Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05985161 · ClinicalTrials.gov registry record · Phase 2
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
A Phase 2 study of Solid Tumor and Wilms Tumor, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 15
- Study locations
NCT05985161: Recruiting Phase 2 study of Solid Tumor and Wilms Tumor, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05985161 is a Phase 2 study of Solid Tumor and Wilms Tumor that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 45 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (80% lower). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05985161, a Phase 2 study of Solid Tumor and Wilms Tumor, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Primary Outcome
To define the antitumor activity of Selinexor in relapsed and refractory Wilms tumor by measuring the Overall Response Rate, defined as Complete Response + Partical Response
Conditions Studied
Interventions
- DRUG Selinexor
Study Locations (15)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activites) - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited protocol activities) - Montvale
California
- Children's Hospital of Los Angeles (Data Collection Only) - Los Angeles
- Stanford Medicine Children's Health (Data Collection Only) - Palo Alto
District of Columbia
- Children's National Hospital (Data Collection Only) - Washington D.C.
Georgia
- Children's Healthcare of Atlanta (Data Collection and Specimen Analysis) - Atlanta
Illinois
- Ann & Robert H. Lurie Children'S Hospital of Chicag - Chicago
Massachusetts
- Dana Farber Cancer Institute (Data Collection Only) - Boston
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 2 |
What NCT05985161 shows while recruiting
NCT05985161 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (80% lower).
The record links to 7 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Selinexor is the first listed.
NCT05985161 lists 15 locations in 9 states (New York, New Jersey, California).
Frequently Asked Questions
What is clinical trial NCT05985161 about?
NCT05985161 is a clinical study titled "A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors". The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
What is the current status of trial NCT05985161?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2023-08-01. Estimated completion is 2029-08-01.
What conditions does trial NCT05985161 study?
This clinical trial studies the following conditions: Solid Tumor, Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST.
What interventions are being tested in trial NCT05985161?
The interventions under investigation include: Selinexor (DRUG).
Who is sponsoring clinical trial NCT05985161?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05985161 being conducted?
This trial has 15 study locations across California, District of Columbia, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05985161's enrollment target sits among peer trials
45 133rd of 196 higher than 62 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
-
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI